Navigation Links
China Sky One Medical, Inc. Provides Update on Filing Form 10-K
Date:4/7/2009

HARBIN, China, April 7 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that an extension notification filed with the Securities and Exchange Commission for its Annual Report on Form 10-K on March 31, 2009, is related to a technical non-cash accounting issue regarding the treatment of 3 million shares of the company's stock owned by China Sky One's Chairman that were placed in escrow as part of its private placement on January 31, 2008 as part of a "make good" provision to achieve specified earnings per share targets, because if the company achieved the targets for both 2007 and 2008, the escrowed shares will be returned to the company's chairman. The company is working closely with its current and prior auditors, and seeking additional guidance from SEC, on the issue as to whether these escrow shares will lead the company to record a non-cash compensation expense during 2008. This is the only outstanding issue that has delayed the filing of its annual report on form 10-K.

On a pro forma basis that excludes the impact of any potential non-cash, non-operational expense related to the "make-good" shares, the Company reaffirmed that it met its prior 2008 revenue estimate of $88-$90 million, and its full year 2008 operational net income estimate of approximately $27-$28 million.

"We want to reassure our shareholders that the delay in the release of our annual results is due to the pending resolution of these complex, non-cash accounting issues and has no bearing on the fundamentals of our business," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "We are currently working with our auditors and the Securities and Exchange Commission to resolve this technical non-cash accounting issue and look forward to issuing our annual results on Form 10-K before April 15, 2009."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the Company's ability to file its Form 10-K within the next fifteen days, risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
    China Sky One Medical, Inc.
     Mr. Yu-Bo Hao, CFO
     Tel:   +86-451-5399-4069
     Email: china_sky_one@yahoo.cn

    Investor Relations Contact:
    CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Agri-Business Announces 2008 Operating Results
2. China Biologic Products Announces Strong 2008 Results
3. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
4. China Biologic Products Completes Acquisition of 35% Interest in Xian Huitian Blood Products Co., Ltd.
5. China Bio Energy Reports Fourth Quarter and Record 2008 Financial Results
6. aTyr Pharma to Present at ChinaBio(R) Investor Forum in Hong Kong
7. Niusule Biotech Corp. Formally Establishes a New Venture to Import and Sell Health Foods in the Peoples Republic of China
8. China-Biotics, Inc. Appoints New Chief Financial Officer
9. China Medical Technologies Senior Management Purchased Company Shares
10. China Bio-Immunity Corporation - Rabies Vaccine Recall
11. China Medicine to Participate in 2009 Natural Products Expo West Trade Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:6/22/2016)... June 22, 2016 On Monday, the Department ... industry to share solutions for the Biometric Exit Program. ... and Border Protection (CBP), explains that CBP intends to ... the United States , in order ... defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
Breaking Biology News(10 mins):